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Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S141engraftment is given. We report a case of a 64-year-old
female with multiple myeloma and secondary engraftment
failure after high dose chemotherapy with autologous he-
matopoietic stem cell transplantation (AHSCT) on day +64.
The patient presented with severe pancytopenia and a
bone marrow biopsy and aspirates revealed a hypocellular
marrow without increased plasma cells. An extensive in-
fectious disease work up was negative for bacterial, fungal
or viral source including cytomegalovirus, HHV 6, parovi-
rus, BK virus, and adenovirus. The patient received stem
cell boost on day +98 and failed to engraft. A repeat bone
marrow biopsy performed on day +127 revealed less than
10% cellularity with no signs of hematopoiesis and no
plasma cells. Therefore, the patient met the criteria for
severe aplastic anemia (AA). The patient was initiated on
eltrombopaq after one week treatment of steroid and
cyclosporine with minimal improvement in neutrophil
counts. Although uncommon, the case study examines the
rare occurrence of AA in the post-transplant population.
The case report highlights that secondary engraftment
failure and AA are uncommon complications of AHSCT and
can be life threatening. Careful clinical evaluation and pa-
thology review are necessary to determine the cause of
graft failure in the autologous transplant setting in order to
provide the appropriate medical and supportive care.161
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Purpose: Engraftment syndrome (ES) is a complication of
autologous hematopoietic stem cell transplantation
(HSCT) characterized by non-infectious fever, skin rash,
diarrhea, and inﬂammatory manifestations. Acute renal
dysfunction is a less frequently reported complication of
ES, occurring in up to 26% of patients. No prior investi-
gation has identiﬁed speciﬁc risk factors for developing
acute renal failure in this patient population. The objec-
tive of this study is to determine risk factors associated
with the development of acute renal dysfunction in pa-
tients with ES.
Methods: This study will be submitted to the University of
Texas Health Science Center and Veterans Affairs Institu-
tional Review Board for approval. This retrospective
cohort study will identify all patients receiving autologous
HSCT from January 2011 to December 2013 at a single
institution. Patients with a diagnosis of ES (per the
Maiolino criteria: non-infectious fever plus one of the
following: skin rash, pulmonary inﬁltrates, or diarrhea
which commences 24 hours before, or any time after
appearance of neutrophils) will be identiﬁed. Potential
risk factors that may lead to the development of acute
renal dysfunction during the time of ES will be analyzed.
Data collected will include: baseline demographics, un-
derlying malignancy, comorbid conditions, mobilization
regimen, conditioning regimen, number of CD34 cells
infused, time of engraftment, date of ﬁrst fever, physical
examination, medications, clinical lab values, and length
of hospital admission. Descriptive statistical analyses willbe performed for discrete variables by using Pearson’s chi-
squared test or Fisher’s exact test appropriately. Risk fac-
tors will be analyzed using a backward stepwise logistic
regression model.162
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Background: In 2014, high-dose chemotherapy with autol-
ogous stem cell rescue (autoSCT) was removed from the
NCCN guidelines as a recommended treatment for patients
<60 years old with intermediate-risk (int-risk) AML in ﬁrst
complete remission (CR1). We comprehensively reviewed
the long-term outcomes of all patients with int-risk AML
treated with autoSCT in CR1 at our institution.
Patients and Methods: This is a retrospective, single insti-
tution study of all patients with int-risk AML treated with
autoSCT in CR1 between 1988-2013. Data were collected by
chart review. Publicly available death indices were accessed
to ensure accurate dates of death, with censoring of data on
September 1, 2014. For all analyses, patients with <1 year
follow-up were considered to have relapsed at the date of
last follow-up. Statistical analyses were performed using
STATA SE 9.
Results: We identiﬁed 133 patients with int-risk AML who
underwent autoSCT in CR1. Cytogenetics were diploid in 97
(73%); FLT3mutation status was only assessed routinely after
2008 (21 patients total, 17/21 negative).
Of the 133 patients, 55% were women and 69% were
Caucasian. Median age at autoSCT was 47 years (range 20-
72). Mean CD34+ cell dose infused was 13 x 106/kg (range
2.6-63). Ten percent of patients were treated pre-1993 with
bone marrow stem cells and PO busulfan (BU), 28% between
1993-2003 with peripheral blood stem cells (PBSCs) and PO
BU, 35% between 2003-2007 with PBSCs and IV BU, and 28%
post-2007 with PBSCs and targeted IV BU (all with 60mg/kg
IV etoposide).
With a median follow-up of 4.3 years (range 0.1-17),
median relapse-free survival (RFS) has not been reached; 52%
of patients remain relapse-free. Fourteen (10%) patients
developed therapy-related MDS or AML. In multivariate
analysis, relapse was predicted by non-Caucasian race (HR
2.5, p¼0.001) and by treatment era post-2007 (HR 1.85,
p¼0.025). Median overall survival (OS) for the entire cohort
is 6.6 years (range 0.1-17).
Twenty-six of 54 relapsing patients (48%) subsequently
received an alloSCT, with 16 (62%) proceeding to alloSCT in
CR2 and 7 (27%) with active disease. Twelve (46%) patients
relapsed following alloSCT. Of the 26 alloSCT patients, 9
(35%) died from treatment-related causes and 9 (35%) from
AML relapse. Median follow-up for patients receiving salvage
alloSCT is 3.8 years (range 0.17-7.8) with 8 (31%) patients
known to be alive and in remission. Median RFS after alloSCT
is 2.5 years (range 0.02-4.32).
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in CR1 achieved sustained remissions using autoSCT. Of
those who relapse, nearly 50% proceed to alloSCT and 31%
are long-term disease-free survivors. Relapse-free survival
has likely decreased in the most recent era due to changes
in patient selection. AutoSCT remains a reasonable option
for int-risk patients with AML in CR1, with outcomes
rivaling those currently achieved with alternative donor
alloSCT.163
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Background: High dose chemotherapy (HDC) followed by
autologous stem cell transplant (ASCT) is considered the
standard of care for patients with multiple myeloma (MM).
With most patients receiving induction therapy that in-
cludes corticosteroids. The combined effect of prior ther-
apy for myeloma and ASCT related complications may
result in hypotension and require intensive medical
treatment. To date the incidence of adrenal insufﬁciency in
the setting of ASCT is unknown. The effects of this under-
lying disorder in regards to post transplant outcome
remain unknown as well. We set out to compare the out-
comes of patients with multiple myeloma who underwent
ASCT with adrenal insufﬁciency compared to those with
sufﬁcient adrenal function.
Methods: This was a prospective study in 13 consecutive
patients with MM admitted for HDC and ASCT at Henry Ford
Hospital between February 2014 through June 2014, with
the ﬁrst patient sample being obtained in on 2/14/2014 and
last sample recorded in 6/23/2014. Random cortisol levels
were obtained on the day of admission or day -2 (Figure 1),
prior to the start of HDC. All prior therapies included
corticosteroids and consisted of the following RVD, DCEP,
RD, VD, DT-PACE. Patients were classiﬁed into twoFigure 1groups those with cortisol levels > 5 and those patients
who had cortisol levels <5. Endpoints analyzed included
hypotension, septic shock, and duration of antibiotic
therapy.
Results: Of the 13 patients analyzed the median age was 60
years old (range 53-78), gender 8 male patients 5 female.
All patients underwent HDC with Melphalan and ASCT. Of
the 13 patients in which data was obtained 3/13 23% had
adrenal insufﬁciency prior to high dose Melphalan and
ASCT. With a median cortisol level of 3.2 in the patient
cohort who were found to be adrenal insufﬁcient. The
incidence of hypotension was 2/3 66% in the adrenal
insufﬁcient patients compared 1/10 10% in the cohort with
sufﬁcient adrenal function. Septic shock occurred in 2/3
66% of the adrenal insufﬁcient compared to 0/10 in the
adrenal sufﬁcient group. The median duration of antibiotic
therapy was 5 days in the adrenal insufﬁcient cohort
compared to 2 days in the patients with adequate adrenal
function.
Conclusion: In this small cohort of consecutive patients from
a single center, we found that there was a high incidence of
adrenal insufﬁciency 23% in patients undergoing ASCT. The
treatment regimens varied in the study group with all pa-
tients receiving corticosteroid therapy in their induction
regimen. Given the unexpectedly high incidence of adrenal
insufﬁciency a consideration should be given to check a
random cortisol level prior to the initiation of HDC. Supple-
mental therapy or treatment should be considered in this
high risk group to avoid unnecessary complications and
prolonged antibiotic use and supportive care in this patient
cohort.
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Background: SCIAR are often seen during transplants, but
enough data are not available. In the past SCIAR were
attributed to adverse event (AE) from DMSO..
